Published in J Neurosci on March 14, 2007
Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull (2012) 2.30
The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia. Stereotact Funct Neurosurg (2009) 2.24
The nature of relapse in schizophrenia. BMC Psychiatry (2013) 1.38
The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry (2014) 1.14
Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull (2011) 1.05
Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. Schizophr Res Treatment (2012) 1.00
Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull (2013) 1.00
Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine. Behav Pharmacol (2012) 0.99
The dopamine dilemma: using stimulants and antipsychotics concurrently. Psychiatry (Edgmont) (2010) 0.95
Antipsychotic drug effects in schizophrenia: a review of longitudinal FMRI investigations and neural interpretations. Curr Med Chem (2013) 0.95
Antipsychotic dosing: how much but also how often? Schizophr Bull (2010) 0.94
Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: roles of number of drug exposure, drug dose, and test-retest interval. Behav Pharmacol (2012) 0.92
Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs (2015) 0.90
Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function. PLoS One (2013) 0.86
Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.86
Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model. J Psychopharmacol (2013) 0.84
Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophr Bull (2014) 0.84
Antipsychotic-induced gene regulation in multiple brain regions. J Neurochem (2010) 0.83
Post-drug consequences of chronic atypical antipsychotic drug administration on the ability to adjust behavior based on feedback in young monkeys. Psychopharmacology (Berl) (2011) 0.82
Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Schizophr Res (2014) 0.81
Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia. Schizophr Bull (2012) 0.81
Dysfunctional Striatal Systems in Treatment-Resistant Schizophrenia. Neuropsychopharmacology (2015) 0.80
Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues. Neuropsychopharmacology (2011) 0.80
Antipsychotic dosing: found in translation. J Psychiatry Neurosci (2014) 0.79
D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection. Psychopharmacology (Berl) (2012) 0.79
Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function. J Psychopharmacol (2015) 0.79
Haloperidol both prevents and reverses quinpirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia. Psychopharmacology (Berl) (2008) 0.79
Powerful choices: peer support and individualized medication self-determination. Schizophr Bull (2009) 0.78
Explaining attitudes and adherence to antipsychotic medication: the development of a process model. Schizophr Res Treatment (2014) 0.76
Antipsychotics and amotivation. Neuropsychopharmacology (2015) 0.76
Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms. J Psychopharmacol (2016) 0.76
Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation. Transl Psychiatry (2014) 0.76
Asenapine sensitization from adolescence to adulthood and its potential molecular basis. Behav Brain Res (2014) 0.76
Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthood. Prog Neuropsychopharmacol Biol Psychiatry (2014) 0.76
Incentive motivation, conditioning, stress, and neuropsychiatric disorders: a tribute to Jane Stewart. Biol Psychiatry (2009) 0.75
Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. Psychopharmacology (Berl) (2016) 0.75
Targeted intermittent treatment in chronic schizophrenia. Front Psychiatry (2013) 0.75
Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia. Int J Mol Sci (2015) 0.75
The psychoactive effects of psychiatric medication: the elephant in the room. J Psychoactive Drugs (2014) 0.75
Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. Electron Physician (2016) 0.75
Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report. Clin Psychopharmacol Neurosci (2017) 0.75
The Dopamine Dilemma-Part II: Could Stimulants Cause Tolerance, Dependence, and Paradoxical Decompensation? Innov Clin Neurosci (2011) 0.75
Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review. Curr Neuropharmacol (2017) 0.75
Delayed yet persistent effects of daily risperidone on activity in developing rats. Behav Pharmacol (2016) 0.75
Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn? NPJ Schizophr (2017) 0.75
Mistakes I Have Made in My Research Career. Schizophr Bull (2017) 0.75
The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) (2002) 9.90
Grand challenges in global mental health. Nature (2011) 8.40
Schizophrenia. Lancet (2009) 8.14
The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull (2009) 6.03
Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry (2012) 4.54
Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl) (2006) 4.23
The consequences of different "lapses" on relapse to heroin seeking in rats. Exp Clin Psychopharmacol (2002) 4.11
Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron (2003) 2.99
A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. N Engl J Med (2015) 2.73
Understanding polydrug use: review of heroin and cocaine co-use. Addiction (2003) 2.68
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry (2007) 2.53
The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry (2012) 2.34
Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala. J Neurosci (2002) 2.26
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry (2003) 2.11
A role for the prefrontal cortex in stress- and cocaine-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berl) (2002) 2.08
Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry (2013) 2.06
Does cerebellar injury in premature infants contribute to the high prevalence of long-term cognitive, learning, and behavioral disability in survivors? Pediatrics (2007) 2.00
Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry (2002) 1.96
The current etiologic profile and neurodevelopmental outcome of seizures in term newborn infants. Pediatrics (2006) 1.95
d-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference. Behav Brain Res (2006) 1.90
Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry (2007) 1.72
An automated method for the extraction of regional data from PET images. Psychiatry Res (2006) 1.67
A cluster randomised controlled trial of the effect of a treatment algorithm for hypertension in patients with type 2 diabetes. Br J Gen Pract (2007) 1.64
Separate brain regions code for salience vs. valence during reward prediction in humans. Hum Brain Mapp (2007) 1.64
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology (2009) 1.62
The central and basolateral nuclei of the amygdala exhibit opposite diurnal rhythms of expression of the clock protein Period2. Proc Natl Acad Sci U S A (2005) 1.59
NMR-based metabolomics study of canine bladder cancer. Biochim Biophys Acta (2012) 1.59
A comparison of two delivery modalities of a mobile phone-based assessment for serious mental illness: native smartphone application vs text-messaging only implementations. J Med Internet Res (2013) 1.58
The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry (2012) 1.58
Increased dopamine D2High receptors in rats reared in social isolation. Synapse (2009) 1.57
The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology (2007) 1.56
Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol Psychiatry (2012) 1.56
Neurodevelopmental outcome in survivors of periventricular hemorrhagic infarction. Pediatrics (2007) 1.55
Microvascular abnormality in schizophrenia as shown by retinal imaging. Am J Psychiatry (2013) 1.53
The facilitative effects of D-cycloserine on extinction of a cocaine-induced conditioned place preference can be long lasting and resistant to reinstatement. Psychopharmacology (Berl) (2008) 1.48
Antipsychotic pathway genes with expression altered in opposite direction by antipsychotics and amphetamine. Synapse (2006) 1.48
D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol (2009) 1.48
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology (2010) 1.47
Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem (2006) 1.42
Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp (2008) 1.40
Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. Arch Gen Psychiatry (2002) 1.39
Temporal difference modeling of the blood-oxygen level dependent response during aversive conditioning in humans: effects of dopaminergic modulation. Biol Psychiatry (2007) 1.39
Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res (2012) 1.38
First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology (2007) 1.38
Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology (2005) 1.35
The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J Biol Chem (2010) 1.33
A circadian rhythm in the expression of PERIOD2 protein reveals a novel SCN-controlled oscillator in the oval nucleus of the bed nucleus of the stria terminalis. J Neurosci (2004) 1.31
Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry (2012) 1.31
Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry (2008) 1.30
Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry (2012) 1.29
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (2012) 1.29
Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. J Neurosci (2005) 1.29
Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. Biol Psychiatry (2012) 1.28
Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J Neurosci (2010) 1.28
Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab (2006) 1.26
Integrating mobile-phone based assessment for psychosis into people's everyday lives and clinical care: a qualitative study. BMC Psychiatry (2013) 1.25
High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol Psychiatry (2005) 1.24
Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology (2006) 1.22
Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology (2005) 1.21
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry (2004) 1.21
A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry (2004) 1.20
Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. Am J Psychiatry (2009) 1.20
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol (2009) 1.19
Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med (2012) 1.19
Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry (2008) 1.17
White matter integrity as a predictor of response to treatment in first episode psychosis. Brain (2013) 1.16
Jumping to conclusions, a lack of belief flexibility and delusional conviction in psychosis: a longitudinal investigation of the structure, frequency, and relatedness of reasoning biases. J Abnorm Psychol (2011) 1.15
Persistence and drug-induced reinstatement of a morphine-induced conditioned place preference. Behav Brain Res (2002) 1.14
Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse (2002) 1.14
Stress and selective attention: the interplay of mood, cortisol levels, and emotional information processing. Psychophysiology (2002) 1.13
Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol (2009) 1.10
Prolonged rewarding stimulation of the rat medial forebrain bundle: neurochemical and behavioral consequences. Behav Neurosci (2006) 1.10
The "delayed onset" of antipsychotic action--an idea whose time has come and gone. J Psychiatry Neurosci (2006) 1.10
An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry (2011) 1.09
A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res (2006) 1.07
The contribution of drug history and time since termination of drug taking to footshock stress-induced cocaine seeking in rats. Psychopharmacology (Berl) (2005) 1.07
Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology (Berl) (2005) 1.07
Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases. Pharmacol Biochem Behav (2004) 1.07
Cocaine self-administration produces a persistent increase in dopamine D2 High receptors. Eur Neuropsychopharmacol (2008) 1.07
Increased dopamine D2(High) receptors in amphetamine-sensitized rats, measured by the agonist [(3)H](+)PHNO. Synapse (2007) 1.06
Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus. Synapse (2006) 1.05
Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharmacology (2006) 1.05
Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry (2010) 1.05
Dopamine, prediction error and associative learning: a model-based account. Network (2006) 1.04
The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology (2008) 1.04
Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement. Neuropsychopharmacology (2005) 1.04
Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull (2008) 1.02
The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspective. Schizophr Res (2011) 1.02
D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology (2008) 1.01
Schizophrenia hippocampus has elevated expression of chondrex glycoprotein gene. Synapse (2003) 1.01